Vaxart, Inc.

Name: Vaxart, Inc. standardized financial statements, quarterly
Creator: Listed

VXRTOTCCIK 72444HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$27.2m, Q2 FY2026

Operating income−$13.2m, Q2 FY2026

Net income−$13.5m, Q2 FY2026

Vaxart, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	2.1	3.2	2.2	6.4	4.9	15.2	20.9	39.7	72.4	104	39.2	27.2
Cost of revenue	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Research and development	$m	15.0	14.7	19.0	17.5	15.1	22.7	30.7	49.7	75.9	45.2	29.4	33.8
Selling, general and administrative	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Operating income	$m	(17.8)	(16.9)	(24.1)	(16.3)	(14.5)	(11.5)	(14.9)	(14.6)	(7.8)	55.4	5.2	(13.2)
Interest expense	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$m	0.0	0.2	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.3	0.0	0.0
Net income	$m	(17.4)	(17.4)	(24.4)	(16.5)	(14.1)	(12.0)	(15.6)	(15.0)	(8.1)	55.0	5.2	(13.5)
Diluted EPS	$ per share	not reported	not reported	not reported	not reported	not reported	not reported	(0.07)	not reported	not reported	not reported	0.02	not reported
Basic EPS	$ per share	(0.11)	not reported	(0.14)	(0.09)	(0.06)	not reported	(0.07)	(0.07)	(0.04)	not reported	0.02	(0.06)

Balance sheet

Cash and equivalents$22.0m, Q3 FY2024

Shareholders' equity$82.4m, Q2 FY2026

Vaxart, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	33.2	34.8	26.7	not reported	22.0	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Current assets	$m	57.1	45.5	44.3	71.5	66.5	68.3	62.6	70.4	117	136	132	117
Total assets	$m	106	91.8	88.7	114	167	166	159	164	209	186	180	165
Current liabilities	$m	11.3	13.7	14.1	15.8	80.4	90.9	98.5	118	169	86.8	76.8	73.1
Total liabilities	$m	34.1	34.0	33.0	33.7	98.2	107	113	131	182	98.3	85.9	82.8
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	71.5	57.8	55.7	80.0	68.4	58.9	45.6	32.9	26.8	87.8	94.1	82.4

Cash flow

Operating cash flow$2.8m, Q2 FY2026

Capital expenditure$35.0k, Q2 FY2026

Vaxart, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(15.0)	(13.5)	(21.2)	(12.0)	(4.2)	(7.3)	(9.6)	(15.9)	2.6	30.7	(2.1)	2.8
Capital expenditure	$m	0.3	(0.1)	0.1	0.4	0.0	0.0	0.1	(0.1)	0.1	0.0	0.4	0.0
Share repurchases	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)242.18m, Q1 FY2026

Vaxart, Inc., shares, quarterly
Line item	Unit	Q1 FY20162015-09-30	Q2 FY20162015-12-31	Q3 FY20162016-03-31	Q1 FY20172016-09-30	Q2 FY20172016-12-31	Q3 FY20172017-03-31	Q1 FY20172017-09-30	Q2 FY20172017-12-31	Q1 FY20182018-03-31	Q1 FY20192019-03-31	Q1 FY20252025-03-31	Q1 FY20262026-03-31
Diluted shares (weighted)	m shares	38.6	38.6	38.6	38.6	38.6	0.1	38.6	38.6	5.3	7.3	228	242

Shares outstanding: 242.84m at Jul 31, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:19 ET. Listed shows no prices and gives no investment advice.